Â鶹ӳ»­

An open-label, multi-cohort Phase II trial, led by investigators at Â鶹ӳ»­ MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies.

Study findings were published...